Who
Cuong Do V
President & CEO
Company insider
Files Form 4 as: President & CEO, BioVie; Director, Adagene; EVP & Chief Strategy Officer, Merck & Company; SVP, Corp. Strategy & Bus. Dev, TE Connectivity.
In numbers
- Trades disclosed
- 69
- Buys
- 5
- Sells
- 0
- Bought
- $96K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 3 Dec 2009
- Last trade
- 27 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 28 Aug 2026 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $32K15,210 at $2.08 | filing |
| 27 Aug 2026filed 28 Aug 2026 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $32K15,210 at $2.08 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ADAG AdageneBiotechnology | SEC FORM 4 Bought | $7,5002,000 at $3.75 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ADAG AdageneBiotechnology | SEC FORM 4 Bought | $7,5002,000 at $3.75 | filing |
| 13 Aug 2026filed 17 Aug 2026 | ADAG Adageneoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | ADAG Adageneoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —665,300 at $0.00 | filing |
| 5 Jan 2026filed 9 Jan 2026 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —665,300 at $0.00 | filing |
| 7 Aug 2025filed 13 Aug 2025 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,000 | filing |
| 7 Aug 2025filed 13 Aug 2025 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | —5,000 | filing |
| 20 Dec 2024filed 7 Jan 2025 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,502 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —227,000 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
| 24 Jun 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $20K42,000 at $0.47 | filing |
| 4 Mar 2024filed 6 Mar 2024 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,000 | filing |
| 4 Mar 2024filed 6 Mar 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | —10,000 | filing |
| 15 Feb 2024filed 12 Jul 2024 | BIVI BioVieBiotechnology | SEC FORM 4 Code F | $5,8454,953 at $1.18 | filing |
| 30 Nov 2023filed 1 Dec 2023 | BIVI BioVieBiotechnology | SEC FORM 4 Bought | $18K10,000 at $1.78 | filing |
| 29 Jun 2023filed 3 Jul 2023 | BIVI BioVieoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 29 Jun 2023filed 3 Jul 2023 | BIVI BioVieBiotechnology | SEC FORM 4 Code A | —149,500 at $0.00 | filing |
News
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual MeetingBIVI · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Cuong Do V; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.